May 30th, 2025 – AstraZeneca has issued a voluntary recall notice for select lots of its Airsupra (albuterol/budesonide) inhalers due to a potential defect that could impact medication delivery. Airsupra is a dual-action inhaler used to treat and prevent symptoms of asthma and chronic obstructive pulmonary disease (COPD).
The pharmaceutical company identified a manufacturing issue in a limited number of inhalers that may result in reduced or no dose delivery, which could pose serious health risks for patients relying on the medication for asthma or COPD management.
What Is Airsupra?
Airsupra is a combination inhaler that contains albuterol (a bronchodilator) and budesonide (a corticosteroid). It is prescribed to relieve and control respiratory symptoms such as:
- Shortness of breath
- Wheezing
- Coughing
- Chest tightness
By combining a fast-acting bronchodilator with an anti-inflammatory steroid, Airsupra offers both immediate and long-term relief from asthma and COPD symptoms.
Why Is the Airsupra Recall Happening?
According to AstraZeneca, the recall was initiated after routine quality testing identified some inhalers that may fail to dispense medication properly. Affected inhalers may:
- Deliver inconsistent doses
- Fail to release medication at all
Appear to function normally while not providing an effective dose
This poses a significant concern for individuals who depend on Airsupra to manage acute asthma symptoms or prevent exacerbations of chronic respiratory conditions.
What Should Patients Do If They Use Airsupra?
Patients currently using Airsupra should:
- Check the lot number on their inhaler against the affected batch list provided by AstraZeneca (available on the FDA or AstraZeneca website)
- Continue using the inhaler if it is not part of the recall, unless advised otherwise by a healthcare provider
- Contact your pharmacist or doctor immediately if you suspect your inhaler is not working properly
- Do not stop using your medication without consulting your healthcare provider, as this could result in worsening symptoms
How to Get a Replacement or Report a Problem
If you have an affected inhaler, contact AstraZeneca or your pharmacy for a free replacement. Healthcare providers and patients can also report issues through the FDA’s MedWatch program.
NY Allergy & Sinus Centers Can Help
If you use Airsupra and are concerned about your asthma or COPD treatment, the team at NY Allergy & Sinus Centers is here to help. We offer:
- Same-day appointments
- Asthma and COPD management plans
- Pulmonary function testing
- Medication alternatives and guidance
Schedule an Appointment Today to review your inhaler, assess your symptoms, and explore treatment options.
Stay informed, stay safe — and if you have concerns about your inhaler, speak with an allergy and asthma specialist at NY Allergy & Sinus Centers today.